Fathom Dx – Comprehensive Cancer Genome Profiling

Fathom Dx test report guides the oncologist with treatment selection, evaluates the best combination of therapies, and considers whether the patient will benefit from targeted therapies or immunotherapies.

"Fathom Dx is the first comprehensive liquid biopsy test to incorporate genomic (INDELs, SNVs, SNPs, CNVs, Structural Variants, Gene Fusions) and epigenomic biomarkers (methylation) across the whole genome. Tumour-agnostic biomarkers like TMB, MSI, NTRK gene fusions and Homologous Recombination Deficiency (HRD) status are included in the same test at no extra cost"

- Dr. Shibichakravarthy Kannan, MBBS, PhD, Founder & CEO, Oncophenomics Inc.